Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery

Area of Science:

• Biomedical Engineering
• Materials Science
• Oncology

Background:

• Hypoxia is prevalent in various intractable diseases, posing treatment challenges.
• Targeted drug delivery systems are crucial for enhancing therapeutic efficacy in hypoxic conditions.
• Developing stimuli-responsive nanocarriers is key to overcoming drug resistance in diseases like cancer.

Purpose of the Study:

• To develop self-assembled hypoxia-responsive nanoparticles (HR-NPs) for selective drug release.
• To evaluate the efficacy of HR-NPs loaded with doxorubicin (DOX) for treating hypoxic diseases.
• To investigate the in vitro and in vivo performance of HR-NPs as targeted drug delivery vehicles.

Main Methods:

• Synthesis of HR-NPs by conjugating a 2-nitroimidazole derivative to carboxymethyl dextran (CM-Dex).
• Encapsulation of doxorubicin (DOX) into the prepared HR-NPs.
• In vitro drug release studies under normoxic and hypoxic conditions.
• In vitro cytotoxicity assays on hypoxic and normoxic cells.
• In vivo biodistribution and anti-tumor activity studies in a tumor model.

Main Results:

• HR-NPs demonstrated sustained DOX release under normoxia and significantly increased release under hypoxia.
• DOX-loaded HR-NPs exhibited enhanced cytotoxicity towards hypoxic cells compared to normoxic cells.
• Effective intracellular delivery of DOX into SCC7 cells under hypoxic conditions was observed.
• In vivo studies showed selective accumulation of HR-NPs in hypoxic tumor tissues.
• Drug-loaded HR-NPs displayed significant anti-tumor activity in vivo.

Conclusions:

• HR-NPs are effective nanocarriers for targeted drug delivery in hypoxic environments.
• The developed HR-NPs show potential for treating hypoxia-associated diseases, including cancer.
• This hypoxia-responsive drug delivery system offers a promising strategy for improving therapeutic outcomes.